Visual acuity and its postoperative outcome after transsphenoidal adenoma resection by Butenschoen, Vicki M. et al.
ORIGINAL ARTICLE
Visual acuity and its postoperative outcome after transsphenoidal
adenoma resection
Vicki M. Butenschoen1 & Nina Schwendinger1 & Alexander von Werder2 & Stefanie Bette3 & Maximilian Wienke1 &
Bernhard Meyer1 & Jens Gempt1
Received: 20 May 2020 /Revised: 28 September 2020 /Accepted: 30 September 2020
# The Author(s) 2020
Abstract
Transsphenoidal surgery (TSS) represents the gold standard of pituitary adenoma resection, providing a safe and minimal
invasive treatment for patients suffering from symptoms of mass effect. The aim of this study is to analyze the postoperative
improvement of visual function after adenoma resection and to identify prognostic factors for the postoperative clinical recovery.
We performed a retrospective analysis of all consecutive patients treated via a transsphenoidal approach for pituitary adenomas
from April 2006 to December 2019 in a high-volume neurosurgical department. Our primary outcome was postoperative visual
acuity and visual field impairment; the clinical findings were followed up to 3 months after surgery and correlated with clinical
and radiographic findings. In total, 440 surgeries were performed in our department for tumors of the sella region in a time period
of 13 years via transsphenoidal approach, and 191 patients included in the analysis. Mean age was 55 years, and 98% were
macroadenomas.Mean preoperative visual acuity in patients with preoperative impairment (n = 133) improved significantly from
0.64/0.65 to 0.72/0.75 and 0.76/0.8 (right eye R/left eye L) postoperatively and at 3 months follow-up (p < 0.001). Visual acuity
significantly depended on Knosp classification but not Hardy grading. The strongest predictor for visual function recovery was
age. Transsphenoidal pituitary tumor resection remains a safe and effective treatment in patients with preoperative visual
impairment. It significantly improves visual acuity and field defects after surgery, and recovery continues at the 3 months
follow-up examination.
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Introduction
Pituitary adenomas present benign lesions with a close spatial
relationship to the optic chiasm. Larger tumors growing be-
yond the sella can affect peripheral vision and even cause
elevated intracranial pressure [16, 26, 27]. While the indica-
tion for surgical resection of nonfunctioning incidentalomas is
often a matter of debate and varies from its timing and treat-
ment strategy [23, 24], adenomas leading to visual impairment
are usually treated surgically, in order to improve or halt
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further progression of vision loss [7, 26] as longer duration of
the symptoms has been shown to lead to worse visual out-
comes after surgery [26].
Although the transnasal resection of sellar tumors is
regarded a safe and efficient treatment option, complications
may occur ranging from minor headaches to severe carotid
artery hemorrhage and even death [2, 3, 8, 15]. Factors
influencing the postoperative outcome as well as the compli-
cation rate include age [14, 32, 35], body mass index (BMI)
[9], number of surgeries [15], and the surgical approach used
[18, 29, 34] as well as tumor size and sinus suprasellar growth
[16]. Typical vision changes and field defects include the
bitemporal hemianopsia, leading to binocular vision difficul-
ties [28]. The visual postoperative outcome and recovery are
known to be favorable, although influencing factors are cur-
rently discussed such as preoperative deficits, tumor size und
tumor location, age, duration of symptoms, und tumor recur-
rence [6, 22, 31].
Our study aims to review the postoperative outcome of
patients suffering from visual deficits and identify prognostic
factors influencing the improvement, stagnation, or even
worsening of visual acuity postoperatively and at 3 months
follow-up.
Methods
We conducted a retrospective analysis of all consecutive pa-
tients treated for sella turcica pituitary adenoma from April
2006 to December 2018 in our neurosurgical department
through a transnasal transsphenoidal approach. Inclusion
criteria were adenoma of the sella region, complete data avail-
able, age > 18 years, transsphenoidal transnasal operation per-
formed, minimum follow-up time with assessment of visual
acuity, and perimetric assessment at 3 months.
Demographic factors such as gender, age, and Karnosfky
Performance Status Scale (KPS) as well as comorbidities were
retrieved from patient files. We reviewed preoperative imag-
ing (magnetic resonance imaging MRI, computed tomogra-
phy CT) and obtained detailed information on the preopera-
tive and postoperative visual acuity and visual field defects
(mapping of the visual field using a threshold static automated
perimetry).
Surgical data included microscopic vs. endoscopic ap-
proach, length of operation (minutes), and intraoperative oc-
currence of cerebrospinal fluid (CSF) leaks. Visual acuity and
field defects were examined on postoperative day (POD) 6 as
well as clinical status via KPS. Extent of resection (EOR) was
classified in gross total resection (GTR) vs. partial resection
(PR). Postoperative complications (transient or persistent dia-
betes insipidus, CSF leaks with the need of surgical revision,
neurological deterioration) and tumor histology were
assessed. The minimum follow-up time was 3 months.
We performed statistical correlation analyzes using SPSS
Version 26.0.0.0 and R Version 3.6.3, adjusting for age and
gender by conducting multivariate factor evaluation and con-
trolling for possible confounders. Subgroup analysis was per-
formed for patients suffering from preoperative visual acuity
impairment; chi-square and Fisher’s exact test were used for
significance testing.
Tumor volume and tumor extension were measured and
classified by Knosp et al. for cavernous sinus invasion [17]
and by the Wilson-Hardy classification to describe tumor in-
vasiveness through the sella floor [12], as well as the pituitary
gland delineation (Fig. 1). Preoperative tumor volume was
manually segmented using iPlan Net (iPlan Net Cranial 3.0,
Brainlab AG, Munich) by a neuroradiologist (S.B., 8 years of
experience) and a neurosurgeon (V.B, 5 years of experience).
To assess inter-rater reliability, the intraclass correlation coef-
ficient (ICC) was calculated for 50 randomly chosen subjects
as described before [11].
Results
Patient population
In total, 440 transsphenoidal transnasal surgeries were
performed in 386 patients treated for tumors of the
sellar and parasellar region from January 2006 to
December 2018 in our neurosurgical department. Forty
patients were operated twice, and 7 patients underwent
3 surgeries over the described time period. Fifty patients
were excluded as their histopathological results revealed
sellar pathologies other than adenoma (meningioma,
craniopharyngioma, hypophysitis, Rathke’s cleft cyst);
in 145 patients, preoperative data or follow-up visual
acuity was missing, therefore excluded from analysis
(Fig. 2). Complete data on preoperative, postoperative,
and 3 months follow-up visual acuity and fields was
av a i l a b l e f o r 191 pa t i e n t s ( 4 p a t i e n t s w i t h
microadenoma, 187 patients with macroadenoma). A to-
tal of 69% of the patients suffered from preoperative
impairment of visual acuity (n = 133), and 30.4% had
intact visual acuity (n = 58).
Overall mean and median age were 55 years (range 20–
86 years), and 59.2% (113/191) were male and 41.8% (78/
191) female. Analyzing the subgroup of patients with im-
paired and intact visual acuity, mean age was 50 and 58 years,
respectively (p = 0.001). Table 1 describes the demographic
values of the study populations depending on the visual func-
tion. Overall median preoperative Karnofsky Index was 90%
(interquartile range 80–90%).
Mean tumor volume was 10.41 cm3 (range 1.18–
52.14 cm3, standard deviation of 9.51 cm3), with a me-
dian of 7.32 cm3 (interquartile range 4.36–13.71 cm3).
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The median Knosp grade was 3 (range 0–4), and most
tumors were classified as Wilson-Hardy Class 2 (range
0–4). Inter-rater reliability showed an excellent agree-
ment between the two raters (0.972, 95% confidence
interval 0.757–0.991, p < 0.001).
Preoperative visual field defects
In total, 110/191 patients had specific visual field defect such
as complete or incomplete bitemporal hemianopsia (57.6%):
perimetric findings of bitemporal hemianopsia were
Fig. 2 Flowchart describing the
number of patients meeting the
inclusion and exclusion criteria
and describing the clinical
symptoms at first consultation
grouped by type of visual
impairment
Fig. 1 Volumetric assessment of
tumor size (red), cavernous sinus
invasion (in this case Knosp grade
4), and tumor invasiveness
through the sella floor (Hardy
classification, in this case
classified as class 3) using the
Brainlab software on preoperative
MRI
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diagnosed in 52 patients (47.3% of all patients with visual
field defects, 27.2% of all patients). A total of 54 patients
had specific visual field defects without bitemporal
hemianopsia (49.1% of all patients with preoperative field
defects and 28.3% of all patients).
Unspecific visual field defect changes were registered in 33
patients (30% of all patients with visual field defects, 17.3% of
all patients).
Preoperative visual acuity
Mean preoperative visual acuity was 0.76 for the right and left
eye (R and L).
Visual acuity impairment was found in 133/191 patients
(69.6%). All patients suffered from pituitary macroadenoma.
Mean visual acuity was 0.64 R and 0.65 L. Median Knosp
classification score was grade 3, median Hardy classification
grade 2. Preoperative visual acuity significantly depended on
the Knosp classification (r = − 0.192, p = 0.029) but not on the
grading provided by Hardy at al. (p = 0.395).
Surgical performance
Regarding the intraoperative parameters, 67% (128/191) of
the patients were operated microsurgically and 33% (63/
191) underwent an endoscopic approach. In 27.2% of the
cases, intraoperative CSF flow was noticed (52/191).
Mean surgery duration was 80 min (range 24 to 320 min).
GTR was achieved in 50.8% (n = 97) of the patients, partial
resection in 64.2% (defined as more than 90% tumor resec-
tion, 122/191 patients).
Clinical visual function outcome
One week after surgery, mean visual acuity improved from
0.64R/0.64 L to a value of 0.72R and 0.75 L in patients with
preoperative impairment of visual acuity (p < 0.005) postop-
eratively. At 3 months follow-up, visual acuity continued to
recover with a visual acuity of 0.76 R and 0.80 L (Table 2).
We observed a minor deterioration of visual acuity in pa-
tients with intact preoperative visual function in 12.1% (max-
imum decrease to visual acuity of 0.9 in 7/58 patients), and
84.5% remained stable (49/58). Two patients showed a
Table 1 Patient population with
mean and median age, sex, visual
field defects, and Karnofsky
Performance Status Scale (KPS),
depending on visual acuity
impairment, **p < 0.001
No impairment (n = 58) Visual acuity impairment (n = 133) P value
Age (years) 0.001**
Mean + SD 50 + 16 57.5 + 14.5
Median 49.5 57
Range 20–84 23–86
Sex (n) 0.523
Male 55.2% (32) 60.9% (81)
Female 44.8% (26) 39.1% (52)
Visual field deficit
Yes 27.6% (16) 70.7% (94) 0.000**
With bitemporal hemianopsia 10.3% (6) 34.6% (46) 0.001**
KPS (range)
Median 90% (80–100) 90% (40–100) 0.000**
Tumor volume 6.6 11.6 0.002*
Table 2 Preoperative,
postoperative, and 3-month re-
sults comparing data on visual
acuity and visual field defects in
patients with preoperative visual
impairment. The stars (**) mark
highly significant improvements
of visual function (p < 0.001) and
visual field defects (paired t test
and McNemar test)
PreOP PostOP 3 Mo
FU
Improvement
pre/post OP
Improvement pre
OP/3 months
Visual acuity
With visual impairment
R 0.64 0.72 0.76 0.08** 0.12**
L 0.65 0.75 0.80 0.10** 0.15**
Field defects in patients with visual
acuity impairment
57.6% 42.4% 29.8% 15.2%** 27.8%*
Bitemporal HA 34.6% 23.3% 18.1% 11.3%** 16.5%**
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postoperative decrease but had a complete recovery until
follow-up examination.
Regarding patients with impaired visual function, postop-
erative visual acuity improved in 41.4% and 46.6% for the
right and left eye after surgery (44.4% R and 39.8% L
remained stable). At 3 months follow-up, 48.2% R and
54.4% L had improved and 36% R and 30.7% L remained
stable. The postoperative value, but not the recovery of visual
acuity, significantly depended on the Knosp classification in
bivariate and multivariate analysis (p = 0.004 R and p =
0.03 L vs. p = 0.952). We classified the visual acuity impair-
ment in 3 groups: visual acuity below or equal to 1/10 (n =
10), visual acuity ranging between 1/10 and 5/10 (n = 34), and
visual acuity above 5/10 (total n = 147, n = 89 if excluding
patients with intact visual acuity). In the first group, only
14.3% improved after 3 months; in the second group, 66.7%
had an increase of their visual acuity; and in the third group,
44.2% improved in patient with visual impairment but visual
function above 5/10. The statistical analyses show a signifi-
cant difference between the groups (p = 0.000).
Prognostic factors
The strongest predictor for improvement of visual acuity at
3 months follow-up was age (r = − 0.29, p = 0.001 R and r =
− 0.202, p = 0.019 L); Knosp and Hardy showed an influence
on the visual acuity value but not recovery if controlled for age
in multivariate analysis. Surgery duration and surgical tech-
nique did not influence visual acuity improvement in linear
regression analysis (p = 0.113 and p = 0.603).
Discussion
Our data suggest that transnasal transsphenoidal pituitary sur-
gery is a safe and effective procedure for pituitary adenomas
with a low rate of permanent complications and a satisfying
postoperative outcome by improving the visual acuity signif-
icantly after surgical tumor resection and furthermore visual
function after 3 months.
Most patients experienced an improvement or stagnation of
their visual acuity after surgery in case of preoperative visual
impairment. Our results are comparable with current literature,
rating the improvement from 73 [16] to 67.5% [26] (pooled
review data). Field defects improved in over 75% directly
after surgery and more than 80% after 3 months, compared
with current evidence (range 62 [16] to 81% [26]).
Limitations do occur through the retrospective nature of the
study. Patient data was acquired and reviewed based on infor-
mation available from the endocrinological, ophthalmologi-
cal, and neurosurgical department as well as recruited from
local practice doctors following patients after surgery. Asmild
visual field defects often go unnoticed [5], especially in older
citizens [30], patients may suffer from visual impairment for
several months to years. The duration of symptoms, as a sub-
ject ive pat ient reported factor , can therefore be
underestimating the timing of initial visual deterioration and
influence the potential of visual recovery. A second limitation
is the possible occurrence of comorbidities such as glaucoma
and diabetes-related retinopathy and cataract. These entities
have an impact on visual acuity and field defects [1], are often
unrecognized in the elderly, and present a significant con-
founder in older patients [13]. In our study, we found a sig-
nificant negative correlation between age and recovery of pre-
operative visual acuity impairment, which is most likely
caused by coexisting comorbidities. Nevertheless, elderly pa-
tients did profit from surgical adenoma resection.
Follow-up data was recorded with a minimum time of
3 months. Although patient data was obtained from external
outpatient records, a possible selection bias exists as patients
tend to continue follow-up appointments in case of complicat-
ed postoperative courses. From 386 patients, only 191 could
be included for further analysis due to a lack of complete data.
As pituitary adenoma patients need visual function testing and
endocrinological follow-up, patients may prefer to continue
follow-up examinations closer to their place of residence.
This inclusion of only 50% of the eligible patients presents a
strong limitation.
Quality of life was not assessed in our presented study. In
order to estimate the burden of disease and surgical treatment
effect, patient-reported outcomes and perceived health should
be included in further studies [33] to reflect the true effect of
treatment.
We observed a trend towards a further improvement of
visual acuity on the postoperative timeline, suggesting an on-
going recovery. These positive findings support the theory of
time-dependent convalescence after tumor extirpation, con-
gruent with current literature describing significant improve-
ments after 6 months but not after 3 months [10, 25]. We
found a significant recovery after short-time follow-up of
3 months; the overall treatment effect may therefore be
underestimated compared with long-term analysis after 1 year.
Unfortunately, we did not explore the visual recovery on a
longer interval, but published data suggests even better results
the later the analysis.
The last limitation of our study is the issue of minimum
clinically important difference of visual acuity and visual field
defects. Even though our patients had a statistically significant
improvement of visual acuity, it does not answer the question
of self-perceived subjective improvement. As visual impair-
ment often goes unnoticed, we do not know if patients really
experience their numerical increase of visual acuity or which
value of increase subjectively impacts the patient.
Unfortunately, no studies have answered the question which
minimal amount of visual acuity leads to a subjective im-
provement in patients with pituitary adenoma. The only study
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identified, analyzing the minimum clinical difference in visual
acuity, was conducted in older cataract patients and found a
value of 0.41 [4]. This value seems rather high, and as de-
scribed before, visual function changes in older patients may
go unnoticed.
Our retrospective study focused on clinical factors
predicting visual function recovery. Recent publications re-
ported on more objective measurements to assess the progno-
sis, such as parafoveal and peripapillary perfusion [20], retinal
nerve fiber layer thickness [21], and electrophysiological test-
ing [19]. These measurements, together with clinical parame-
ters and symptoms should be accounted all together to prevent
irreversible optic nerve damage.
Conclusion
In this study, we provide detailed data on the postoperative
visual outcome of patients suffering from sellar tumors treated
via TSS for visual impairment. Visual function seems to re-
cover on a long-term basis, and visual acuity and visual field
defects significantly improved after 1 week and continued to
improve after 3 months. If possible, transnasal adenoma re-
section should be performed in all patients with preoperative
visual impairment.
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